ImmuPharma CEO on P140 progress and expanded pipeline with Kapiglucagon
17 March 2026
ImmuPharma PLC (AIM:IMM, FRA:25I) CEO Tim McCarthy joined Stephen Gunnion in the Proactive studio to discuss the company’s latest developments, including progress on its lead asset P140, a newly accelerated program for Kapiglucagon, and recent fundraising activity. – March 2026